作者：
R C,Coombes [1]
;
Sacha,Howell [2]
;
Simon R,Lord [3]
;
Laura,Kenny [1]
;
Janine,Mansi [4]
;
Zahi,Mitri [5]
;
Carlo,Palmieri [6]
;
Linnea I,Chap [7]
;
Paul,Richards [8]
;
William,Gradishar [9]
;
Sagar,Sardesai [10]
;
Jason,Melear [11]
;
Joyce,O'Shaughnessy [11]
;
Patrick,Ward [10]
;
Pavani,Chalasani [12]
;
Tobias,Arkenau [13]
;
Richard D,Baird [14]
;
Rinath,Jeselsohn [15]
;
Simak,Ali [1]
;
Glen,Clack [16]
;
Ashwani,Bahl [16]
;
Stuart,McIntosh [16]
;
Matthew G,Krebs [17]
作者单位：
Imperial College, South Kensington, London, UK.
[1]
Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
[2]
Early Phase Clinical Trials Unit, Department of Oncology, University of Oxford, Oxford, UK.
[3]
Guy's and St Thomas' NHS Foundation Trust, London, UK.
[4]
OHSU Knight Cancer Institute, Portland, OR, USA.
[5]
University of Liverpool, Liverpool, UK.
[6]
University of California, Los Angeles, CA, USA.
[7]
Blue Ridge Cancer Center, Salem, VA, USA.
[8]
Northwestern University, Chicago, IL, USA.
[9]
US Oncology Research, OHC, Cincinnati, OH, USA.
[10]
Baylor University Medical Center, Texas Oncology, Dallas, TX, USA.
[11]
University of Arizona Cancer Center, Tucson, AZ, USA.
[12]
Sarah Cannon Research Institute, London, UK.
[13]
Cancer Research UK Cambridge Centre, Cambridge, UK.
[14]
Dana-Farber Cancer Institute, Boston, MA, USA.
[15]
Carrick Therapeutics, Dublin, Ireland.
[16]
Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK. matthew.krebs@manchester.ac.uk.
[17]
DOI
10.1038/s41467-023-40561-x
PMID
37550302
发布时间
2023-11-17
换一批
换一批
